Circadian Genes and Risk for Prostate Cancer

Abstract

We propose that genetic susceptibility to prostate cancer may be in part due to variations in the core circadian genes that regulate circadian rhythms and that serum sex steroid hormone levels modify the effect of circadian gene polymorphisms on prostate cancer risk. Our study is nested within the Prostate Cancer Prevention Trial (PCPT), a randomized placebo-controlled clinical trial to determine if finasteride (an inhibitor of androgen bioactivation) could prevent prostate cancer. In Year 2 of the award, we were approved by the DoD to changed our contracting genotyping facility to the University of Texas Health Science Center at San Antonio (UTHSCSA), which was mandated by the PCPT executive committee, and have been involved in analyzing serum androgen data that will be used for Aim 2 of our study. We have been working with the UTHSCSA to ensure that the genotyping assays for our study using the new genotyping platform will be successful. We have also had the DNA samples re-plated at the PCPT biorepository and shipped to UTHSCSA for genotyping.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2010
Accession Number
ADA535308

Entities

People

  • Ann W Hsing

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Biological Sciences
  • Biology
  • Biomedical Research
  • Circadian Rhythms
  • Clinical Trials
  • Department Of Defense
  • Hormones
  • Information Operations
  • Management Personnel
  • Neoplasms
  • Prostate
  • Prostate Cancer

Readers

  • Clinical Trial Research.
  • Molecular and genetic basis of cancer.
  • Prostate Cancer Biology.

Technology Areas

  • Biotechnology